1Medipol University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey
2Medipol University Faculty of Medicine, Department of Cardiovascular Surgery, Istanbul, Turkey
3Medipol University Faculty of Medicine, Department of Radiology, Istanbul, Turkey
4Medipol University Faculty of Medicine, Department of General Surgery, İstanbul, Turkey
An outbreak of a new type coronavirus (COVID-19) disease firstly emerged in Wuhan City, China in December 2019, rapidly spreads across the globe. COVID-19 predisposes a procoagulant state in severe COVID-19 cases with a significant increase in the incidence of venous thromboembolism, including both pulmonary embolism and deep vein thrombosis that appear to be associated with excessive inflammation, hypoxia, immobilization, and diffuse intravascular coagulation. As the thromboembolic risk of COVID-19 patients at home is not known, a risk assessment model for thrombosis may also be considered in these patients. Herein, we present a patient with mild COVID-19 infection who developed acute deep vein thrombosis.
Keywords: COVID-19, deep vein thrombosis, thromboprophylaxis